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ABSTRACT: Human Papilloma Virus (HPV) infection causes different cancer diseases. Cervical 
cancer is the most common HPV related disease. HPV infection also causes cancer of anus, vulva, 
vagina, penis, skin, bladder, prostate, breast, oral and others because the HPV virus is epithelium-
tropic. But the association of HPV infection other than cervical cancer, for example breast cancer, 
bladder cancer, prostate cancer etc is still inconclusive. Thus, the objective of this review was to 
collect published information on HPV infection other than cervix to explore the pooled prevalence of 
HPV infection as well as related types of cancers.  Publish research articles of HPV infection and 
cancer risks other than cervical cancer were systematically searched through Internet. The 
preferred reporting items for systematic review and meta-analysis guidelines were followed. 
Joanna Brigg’s Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI-
MAStARI) adapted for cross sectional/case control study design was used for quality assessment of 
each individual study. A total of 22 studies were extracted and analyzed using STATA 14. The 
random effect model was used to estimate the pooled prevalence; whereas subgroup analysis and 
meta-regression was performed to identify the probable source of heterogeneity. Both Egger’s and 
Begg’s tests were used to check publication bias.  The totals of 486 studies were retrieved and 22 
studies were included in this meta- analysis. The meta-analysis result showed that the pooled 
prevalence of HPV infection other than cervix was 34.36% (95% CI: 23.75, 44.97) with severe 
heterogeneity (I2 = 99.5%; p<0.001) with no publication bias. The highest pooled prevalence of HPV 
infection other than cervix was related to genital cancer which is 58.63% (95% CI: 51.86, 65.39), 
followed by oral cancer (47.15% with 95% CI: 19.67, 74.63). Although cervical cancer is primarily 
HPV induced cancer which well articulated with so many researches, other cancer types (based on 
the location of the HPV infection) are also increasing across the world based on this systematic and 
meta-analysis study. HPV infection increases the risk of developing cancers other than cervical 
cancer.  
 





Human Papillomavirus (HPV) is a group of 
viruses that are extremely common globally. HPV 
is a non-enveloped small (8000bp) DNA virus 
with circular double stranded DNA, mainly 
infects epithelia cells of skin and mucosal 
membrane (Münger, Baldwin et al. 2004, Asiaf, 
Ahmad et al. 2014). 
 There are more than 200 types HPV 
identified, of which many do not caused 
problems (Woodman, Collins et al. 2007). Based 
on the association between cancers, HPV types 
can be classified as high risk HPV and low risk 
HPV (Muñoz, Bosch et al. 2003). Infections with 
low risk HPV types like HPV 6, 11, 40, 42, 43, 44, 
54, 61, 70, 72, 81 etc does not cause symptoms 
and disappear when the body builds immunity 
to the virus (Tadlaoui, Hassou et al. 2020). But 
infections with high risk HPV types like HPV 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82 
etc cause different cancers (Yete, D'Souza et al. 
2018).  
HPV infection causes different cancer 
diseases and cervical cancer is the most common 
HPV related disease (Serrano, Brotons et al. 2018). 
HPV infection also causes cancer of anus, vulva, 
vagina, penis, skin, bladder, prostate, breast, oral 
and others because the HPV virus is epithelium-
tropic (Parkin 2006). But the association of HPV 
infection other than cervical cancers, for example 
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breast cancer, bladder cancer, prostate cancer etc 
is still inconclusive.  
Cervical cancer is the fourth most common 
cancer in women (Small, Bacon et al. 2017). 70% 
of cervical cancer is caused by HPV type 16 & 18 
(Bryan 2007). About 4.5% of all cancers 
worldwide (630,000 new cancer cases per year) 
are attributable to HPV: 8.6% in women and 0.8% 
in men (de Martel, Plummer et al. 2017). HPV 
infection and cervical cancer relations were well 
studied and already awareness was created 
about the risk. But HPV infection related cancers 
other than cervical cancer did not get attention 
among researchers, policy makers or in different 
charity organizations.  Thus, the objective of this 
review was to collect published information on 
HPV infection other than cervix to explore the 
pooled prevalence of HPV infection as well as 
related types of cancers.  This systematic analysis 





Searching strategies  
This systematic review and meta-analysis 
designed to estimate the pooled prevalence of 
HPV infection and related types of cancer risk. 
Initially systematic review and meta-analysis, 
including registered protocols were searched to 
avoid duplications and it was confirmed that 
there was no any review and meta-analysis was 
conducted to HPV infection and cancer risk other 
than cervix. Published research reports of HPV 
infection and cancer risks other than cervical 
cancer were searched. We systematically 
reviewed and analyzed published research 
articles to determine the pooled prevalence of 
HPV infection and its related cancer type. To 
identify published articles, major databases such 
as Pub med/Medline, Cochrane library, Goggle 
and Google scholar were used. In addition, 
reference lists were used. The key used in search 
was “prevalence” or “infection” and “HPV” and 
“risk cancer” and “HPV type”. The search was 
conducted from September 1, 2020 to October 1, 
2020. I followed the preferred reporting item for 
systematic review and meta-analysis (PRISMA) 
guideline during the systematic review (Liberati, 
Altman et al. 2009).  
 
Eligibility criteria  
All studies which report the prevalence of 
HPV infection and cancer risk, and case control 
and cross sectional study designs were included 
under this systematic review and meta-analysis. 
Articles published in English language and 
studies conducted worldwide were included. 
Published articles until September 1/2020 were 
eligible for this review. But studies difficult to 
access full text, not English language, studies 
which do not report specific outcome of HPV 
infection and studies done on cervical cancer 




Data were extracted using a standardized 
data extraction spreadsheet. In data extraction 
sheet study characteristics such as authors name, 
country, publication year, study design, sample 
size; prevalence of HPV infection; type of cancer 
were included. 
 
Quality Assessment of studies 
The Database search results were combined 
and duplicate articles were removed manually 
using Endnote (version X7). Joanna Briggs 
Institute meta-analysis of Statistics Assessment 
and Review Instrument (JBT-MAStARI) adapted 
for both cross sectional and case control study 
design was used (Schultz and Florence 2007). 
Three independent reviewers critically evaluated 
each individual paper. Discrepancies between 
those reviewers were solved by discussion. If 
not, a third reviewer was involved to resolve 
inconsistencies in between the two independent 
reviewers. Studies which score five and above 
from a total of 9 score were included in the final 
systematic review and meta-analysis.  
 
Outcome measurement 
This review and meta-analysis has two 
main outcomes. The primary outcome was 
prevalence of HPV infection and the second 
outcome was HPV infection related cancer types.  
 
Data analysis 
The extracted data were entered into an 
excel sheet and imported to STATA version 14 for 
meta-analysis. Heterogenicity among reported 
prevalence was assessed by using the inverse 
variance (I2) with Cochran Q statistic of 25%, 50% 
and 75% as low, moderate and sever 
heterogenicity respectively with p-value less 
than 0.05 (Tate and Brown 1970). Random effect 
meta-analysis model was used to estimate the 
pooled prevalence of HPV infection. The forest 
plot was also used to visualize the presence of 
heterogenicity graphically. Possible differences 
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between the studies were explored by sub-group 
analysis and meta-regression. The finding was 
presented using forest plot with respective odds 
ratio and 95% confidence intervals. Evidence of 
publication bias was assesses using both Egger’s 
and Begg’s tests with p-value of less than 0.05 as 
a cutoff point to declare the presence of 
publication bias (Sutton, Abrams et al. 2000, 





Selection of studies  
A total of 486 articles searched through the 
electronic search of which 156 duplicate articles 
were excluded. From the remaining 330 articles, 
306 articles were excluded after reading of titles 
and abstracts. Finally, 24 full text articles were 
assessed for eligibility criteria. Based on the pre-
defined criteria and after criteria appraisal (two 
articles excluded) (Ammatuna, Giovannelli et al. 
2008, Siegler, Shiner et al. 2017), 22 articles were 
included in the final analysis (Figure 1). 
Characteristics of included studies  
The total 22 articles were included in this 
meta-analysis and systematic review that meets 
the inclusion criteria. All the included studies 
were published from 2000 up to 2019. All 
included studies used either cross sectional or 
case control study design. A total of 8967cancer 
suspected individuals participated in these 
studies using an estimated sample size range 
from 30 (Makiyama, Hirai et al. 2013) up to 3393 
(Zhao, Wu et al. 2018) to estimate the pooled 
prevalence of HPV infection and cancer risk other 
than cervix. From the total of 22 articles, 5 
studies in USA; 3 study in India; 3 study in Iran; 
1 study conducted in China; 1 study in Denmark; 
1 study in England; 1 study in Germany; 1 study 
in Iraq; 1 study in Japan; 1 study in Mexico; 1 
study in Netherland; 1 study in Oman; 1 study in 
Sweden and 1 study in Spain. The results were 
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2 full articles excluded with reasons 
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22 full text articles included in this 
systematic and meta-analysis  
 
 




Pooled prevalence of HPV infection other than 
cervix (Meta-analysis) 
The pooled prevalence of HPV infection 
other than cervix was 34.36% (95% CI: 23.75, 
44.97) (Figure 2). As shown in the forest plot 
below, statistically significant heterogeneity was 
identified (I2 = 99.5%; p<0.001) indicating that 
the use of random effect models for estimating 
the pooled estimate is applicable. The significant 
magnitude of the heterogeneity also suggests the 
need to conduct subgroup analysis to identify 
the source of heterogeneity (Figure 2).  
Subgroup analysis  
Subgroup analysis was done based on 
study country (Figure 3), study design, 
publication year and cancer type to identify the 
possible source of heterogeneity across the 
studies (Table 2). The subgroup analysis result 
directed that the source of heterogeneity was not 
due to study country, publication year, cancer 
type and detection methods (the overall p-value 




Table 1. Characteristics of 22 included studies to estimate the pooled prevalence of HPV infection and cancer 
risk other than cervix.   
 
ID  Authors  Publicatio
n year 










1 Gillison et al 2000 USA case control PCR 253 25 Head and 
neck 
cancer 
2 Jatin  et al  2002 India cross 
sectional 
PCR 110 33.6 Oral cancer 
3 Harwood et al 2004 England  case control PCR 124 62.9 Skin cancer 
4 Smith et al 2004 USA case control PCR 201 22.9 Head and 
neck 
cancer 
5 Katiyar et al 2005 India  cross 
sectional 
PCR 101 44 Oral cancer 
6 Moonen et al l 2006 Netherland cross 
sectional 
PCR 107 15.2 Bladder 
cancer 
7 Krustrup et al 2008 Denmark  cross 
sectional  
PCR 145 61 Genital 
cancer 
8 Patel et al 2008 Germany case control PCR 239 20 Skin cancer 
9 Escutia  et al 2010 Spain  case control PCR 142 21.2 Skin cancer 
10 Larsson et al 2012 Sweden cross 
sectional 
PCR 69 53.6 Genital 
cancer 
11 Kiyoshi et al 2012 Japan case control Hybrid 30 69.2 Oral cancer 
12 Michuad et al 2015 USA cross 
sectional 
PCR 1069 14.8 Oral cancer  
13 Hussein et al 2016 Iraq cross 
sectional 
PCR 104 12.5 Any type  
14 Fatemeh et al  2016 Iran cross 
sectional 
PCR 200 20 Prostate 
cancer 
15 Doosti et al 2016 Iran cross 
sectional 
PCR 47 22.9 Breast 
cancer 
16 Gheit et al 2017 India  cross 
sectional 
PCR 364 13.7 Head and 
neck 
cancer 
17 Luna-Aguirre et 
al 
2017 Mexico  cross 
sectional  
PCR 724 87 Any type  
18 Fu Xi et al 2018 USA cross 
sectional 
PCR 1090 5 Skin cancer 
19 Zhao et al 2018 China cross 
sectional 
PCR 3393 15.1 Any type  
20 Agalliu et al 2019 USA case control PCR 125 75.7 Oral cancer 
21 Al-lawati et al 2019 Oman cross 
sectional 
PCR 258 17.8 Any type  
22 Niloofar et al 2019 Iran case control PCR 72 48.6 Breast 
cancer 
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 99.5%, p = 0.000)
Doosti etal (2016)
Harwood etal (2003)
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Figure 2. Forest plots showing the pooled prevalence of HPV infection other than cervix.  
 
The lowest pooled prevalence of HPV infection 
other than cervix was indicated in usa [28.21% 
(95% CI: 14.41, 42.02)] (Figure 3). There was 
decrement of HPV infection other than cervix 
starting from 2015 (30.19% (95% CI: 14.56, 45.82)) 
(Table 2). The highest pooled prevalence of HPV 
infection other than cervix was related to genital 
cancer, secondly oral cancer is the highest 
prevalence and breast cancer is in the third rank 
(Table 2 and Figure 4).   
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Figure 3. Forest plot shows subgroup analysis of HPV infection other than cervix by country.  
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Table 2. Subgroup analysis which indicates the pooled prevalence of HPV infection other than cervix.  
 
Subgroups No. of 
studies  






I2   
(%) 
Cancer type  Head and Neck 
cancer  
3 20.29(12.65,27.94) 14.98 0.001 86.6 
Oral cancer  5 47.15(19.67,74.63) 297.64 <0.001 98.7 
Skin cancer 4 26.95(7.05,46.84) 216.70 <0.001 98.6 
Genital cancer 2 58.63(51.86,65.39) 1.04 0.307 4.2 
Breast cancer 2 35.80(10.62,60.99) 9.14 0.003 89.1 
Others 6 27.97(-3.39,59.34) 2730.78 <0.001 99.8 
Detection 
method 
PCR 21 32.84(22.03,43.65) 4000.01 <0.001 99.5 
Hybridization  1 69.2(52.68,85.72) 0 <0.001 99.5 
Study design  Cross sectional  14 29.62(16.12,43.11) 3656.49 <0.001 99.6 
Case control  8 42.65(27.49,57.80) 254.07 <0.001 97.2 
Publication year  Before 2015  11 38.22(27.98,48.46) 210.15 <0.001 95.2 
2015 and above  11 30.19(14.56,45.82) 3722.16 <0.001 99.7 
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Figure 4. Forest plot shows subgroup analysis of HPV infection other than cervix by cancer type. 
 
 
Publication bias  
In addition to subgroup analysis, 
publication bias as source of heterogeneity was 
also checked using both Begg’s and Egger’s tests 
using STATA version 14. The result of Begg and 
Egger tests were not identified as the source of 
heterogeneity pooled prevalence of HPV infection 
other than cervix at p-value of (p=0.003) and 
(p=0.104) respectively.  
 
Meta regression  
Besides subgroup analysis and publication 
bias, meta regression was also assumed by 
considering both continuous and categorical data 
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to identify associated factor of heterogeneity for 
the pooled prevalence of HPV infection other than 
cervix. Study country, sample size, publication 
year and study design were considered in meta-
regression. However, the Meta regression 
indicated that the pooled prevalence of HPV 
infection other than cervix was not associated 
with study country, sample size, publication year 
and study design (Table 3). 
 
Table 3. Meta regression to identify the source of 
heterogeneity for the prevalence of HPV 






P –value  
Study 
country  
Iran  3 Reference  Referenc
e  
USA 5 -1.8704 0.921 
India 3 -0.1106 0.996 
Others  11 8.9016 0.598 
Sample  Sample 
size  
22 -0.0083 0.249 
Publicatio
n year  
Before 
2015 




















This systematic review and meta-analysis was 
conducted to estimate the pooled prevalence of 
HPV infection other than cervix and related types 
of cancers from 2000 to 2019. According to this 
systematic review and meta-analysis, more than 
one third (34.36%) of participants were infected 
with HPV other than cervix. Genital cancers and 
oral cancers were more frequent related diseases 
with HPV infection other than cervix. The 
prevalence of HPV infection other than cervix is 
decreasing after 2015 based on the meat-analysis 
result of this study. In this meta- analysis low 
prevalence of HPV infection other than cervix 
have been seen in USA compared to India and 
Iran.  
The prevalence of HPV infection other than 
cervix in this systematic review and meta-
analysis is lower than with study done by (Ortiz, 
Tamayo et al. 2017), (Fernandes, Meissner Rde et 
al. 2009), (So, Lee et al. 2019) and (Ghosh, Shetty 
et al. 2019). But it is higher than the study done 
by (Shrivastava, Agrawal et al. 2015), 
(Chikandiwa, Pisa et al. 2019), (Guan, Howell-
Jones et al. 2012) and (Ferré, Ekouevi et al. 2019). 
(de Martel, Plummer et al. 2017)  reported than 
the prevalence of HPV infection was <3% in USA 
and >20% India. In this meta-analysis also the 
prevalence was higher in India than USA. But it 
is lower than the overall prevalence of HPV in 
USA and India summarized in this meta-
analysis. These disparities may be due to sample 
size and study methodologies difference 
between this meta-analysis and other studies. 
Regarding the issue HPV infection induced 
cancers; it is obvious that many research finding 
reported than cervical cancer primarily 
associated cancer type. But there are also other 
cancer types related with HPV infection. A study 
by (Mirghani, Sturgis et al. 2017)  showed that 
there is an increasing risk tongue or tonsil 
cancers (oral cancers) which could be an 
indication of HPV infection in different 
anatomical locations cause cancers both in men 
and women.  
This meta-analysis study has certain 
limitations which includes only articles publish 
in English language and there are also research 
articles which didn’t included to this review due 





Although cervical cancer is primarily HPV 
induced cancer, other cancer types (based on the 
location of HPV infection) are also increasing 
across the world. More than 34.36% of 
participants included in this study were infected 
with HPV other than the cervical region. This 
increases the risk of development of cancers 
other than cervix induced by HPV infection. 
Therefore, countries and health organizations 
should also give attention to risk of other cancers 
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